Compare Quest Diagnostics Inc (DGX) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Equinor ASA — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Equinor ASA trades at $43.01 (market cap $101.62B). The key difference: Equinor ASA is far larger — about 4× Quest Diagnostics Inc's market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Equinor ASA for 59 Days on average.
| DGX | EQNR | |
|---|---|---|
Market Cap | $25.48B | $101.62B |
Volume | 941,866 | 4,991,782 |
Sector | Health | Energy |
52-Week High | $247.45 | $45.75 |
52-Week Low | $173.49 | $22.41 |
Typical Hold Time | 56 Days | 59 Days |
Enterprise Value | $31.23B | $110.31B |
Dividend Yield | 1.49% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
EQNR trades at $42.93, up 3.17% today, with a bullish technical outlook supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39, while maintaining strong profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues expanding its LNG portfolio with new Asian supply agreements.
EQNR presents compelling value with significant upside to the $87.50 consensus price target. However, declining revenue and net income margins since 2022, coupled with negative net cash flow trends, warrant caution. The stock's performance remains sensitive to energy market volatility and execution of LNG expansion plans through the early 2030s.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
